Analysts expect Horizon Pharma PLC (NASDAQ:HZNP) to report $254.14 million in sales for the current quarter, according to Zacks. Two analysts have issued estimates for Horizon Pharma PLC’s earnings, with the lowest sales estimate coming in at $249.55 million and the highest estimate coming in at $258.72 million. Horizon Pharma PLC posted sales of $208.70 million in the same quarter last year, which would indicate a positive year-over-year growth rate of 21.8%. The business is scheduled to announce its next earnings report on Monday, November 6th.

On average, analysts expect that Horizon Pharma PLC will report full-year sales of $254.14 million for the current year, with estimates ranging from $1.02 billion to $1.04 billion. For the next fiscal year, analysts anticipate that the company will post sales of $1.07 billion per share, with estimates ranging from $1.05 billion to $1.08 billion. Zacks Investment Research’s sales averages are a mean average based on a survey of research analysts that cover Horizon Pharma PLC.

Horizon Pharma PLC (NASDAQ:HZNP) last released its quarterly earnings results on Monday, August 7th. The biopharmaceutical company reported $0.41 earnings per share for the quarter, topping the consensus estimate of $0.12 by $0.29. Horizon Pharma PLC had a negative net margin of 42.40% and a positive return on equity of 22.85%. The business had revenue of $289.51 million for the quarter, compared to analysts’ expectations of $237.01 million. During the same period in the previous year, the company earned $0.56 earnings per share. The firm’s revenue for the quarter was up 12.5% compared to the same quarter last year.

A number of research firms have weighed in on HZNP. UBS AG set a $16.00 price objective on shares of Horizon Pharma PLC and gave the company a “buy” rating in a research note on Wednesday, June 7th. Cantor Fitzgerald restated an “overweight” rating and set a $17.00 price objective (up from $13.00) on shares of Horizon Pharma PLC in a research note on Wednesday, August 9th. Zacks Investment Research upgraded shares of Horizon Pharma PLC from a “sell” rating to a “hold” rating in a research note on Friday, August 11th. BMO Capital Markets restated a “buy” rating and set a $17.00 price objective on shares of Horizon Pharma PLC in a research note on Friday, July 28th. Finally, Piper Jaffray Companies set a $18.00 price objective on shares of Horizon Pharma PLC and gave the company a “buy” rating in a research note on Monday, August 7th. Five investment analysts have rated the stock with a hold rating, ten have given a buy rating and one has issued a strong buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus target price of $18.67.

Large investors have recently modified their holdings of the business. Bank of Montreal Can lifted its holdings in Horizon Pharma PLC by 16.3% during the second quarter. Bank of Montreal Can now owns 9,809 shares of the biopharmaceutical company’s stock valued at $116,000 after purchasing an additional 1,378 shares in the last quarter. Sheaff Brock Investment Advisors LLC lifted its holdings in Horizon Pharma PLC by 5.0% during the second quarter. Sheaff Brock Investment Advisors LLC now owns 10,500 shares of the biopharmaceutical company’s stock valued at $125,000 after purchasing an additional 500 shares in the last quarter. Family Management Corp purchased a new position in Horizon Pharma PLC during the second quarter valued at approximately $131,000. Ballentine Partners LLC purchased a new position in Horizon Pharma PLC during the second quarter valued at approximately $139,000. Finally, Massachusetts Financial Services Co. MA purchased a new position in Horizon Pharma PLC during the first quarter valued at approximately $151,000. 82.30% of the stock is currently owned by institutional investors and hedge funds.

Horizon Pharma PLC (HZNP) traded up 1.32% on Monday, reaching $12.27. 2,021,226 shares of the company traded hands. The company’s market capitalization is $2.00 billion. The stock’s 50 day moving average price is $12.81 and its 200 day moving average price is $12.94. Horizon Pharma PLC has a one year low of $9.45 and a one year high of $21.98.

COPYRIGHT VIOLATION NOTICE: “Horizon Pharma PLC (HZNP) Expected to Post Quarterly Sales of $254.14 Million” was posted by Daily Political and is owned by of Daily Political. If you are viewing this article on another site, it was copied illegally and republished in violation of US & international trademark and copyright law. The correct version of this article can be viewed at https://www.dailypolitical.com/2017/09/21/horizon-pharma-plc-hznp-expected-to-post-quarterly-sales-of-254-14-million.html.

About Horizon Pharma PLC

Horizon Pharma Public Limited Company is a biopharmaceutical company. The Company is focused on identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. As of December 31, 2016, the Company marketed 11 medicines through its orphan, rheumatology and primary care business units.

Get a free copy of the Zacks research report on Horizon Pharma PLC (HZNP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Horizon Pharma PLC (NASDAQ:HZNP)

Receive News & Ratings for Horizon Pharma PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Pharma PLC and related companies with MarketBeat.com's FREE daily email newsletter.